Efficacy and Safety of FGFR Inhibitor Monotherapy versus Combination with Immune Checkpoint Inhibitors in FGFR-Altered Advanced or Metastatic Urothelial Carcinoma: AMeta-Analysis
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
will evaluate the robustness of our primary findings and determine whether any single study or outlier disproportionately influences the overall pooled effect size or heterogeneity. Country(ies) involved China.
Fields of Study & Subjects
Bladder and Urothelial Cancer Treatments
Fibroblast Growth Factor Research
Lung Cancer Treatments and Mutations
Publication details
- Publication date
- 16 March 2026
- Language
- EN